Regret concerning treatment decisions in patients with primary or secondary brain tumors – a cross-sectional exploratory bicentric analysis - Top-Institutions - MDSpire

Regret concerning treatment decisions in patients with primary or secondary brain tumors – a cross-sectional exploratory bicentric analysis

  • By

  • Julia Reuter

  • Tim Werfel

  • Alexander Rühle

  • Georg Wurschi

  • Anja Mehnert-Theuerkauf

  • Johannes Wach

  • Klaus Pietschmann

  • Tomas Kazda

  • Maximilian Römer

  • Nils H. Nicolay

  • Andreas Hinz

  • Clemens Seidel

  • March 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Radiation Oncology
    • Psychosocial Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Medical Oncology
    • Radiation Oncology

  • #3

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Psychosocial Oncology
    • Radiation Oncology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Radiation Oncology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Radiation Oncology
    • Psychosocial Oncology

Original Source(s)

Regret concerning treatment decisions in patients with primary or secondary brain tumors – a cross-sectional exploratory bicentric analysis

  • by Julia Reuter, Tim Werfel, Alexander Rühle, Georg Wurschi, Anja Mehnert-Theuerkauf, Johannes Wach, Klaus Pietschmann, Tomas Kazda, Maximilian Römer, Nils H. Nicolay, Andreas Hinz, Clemens Seidel

  • March 25, 2026

Related Content

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases

Uncommon Progression of BRAF/KRAS Wild-Type Colorectal Cancer: A Case Study of Cerebral Metastasis After Standard Treatment